New laboratory at University Hospital of Wales to support babies and families across Wales

A new newborn screening laboratory is due to open at University Hospital of Wales, helping babies and families benefit from earlier diagnosis and treatment for a wider range of serious health conditions, supported through Welsh Government funding.

Currently in Wales, every baby receives newborn blood spot screening, which tests for a number of rare but serious conditions, including cystic fibrosis, congenital hypothyroidism and sickle cell disease. The screening programme helps identify babies who may be affected by these conditions, enabling them to access specialist care, treatment and support as early as possible.

The new biochemistry laboratory at UHW will provide the space and facilities needed to expand screening in the future, including the introduction of testing for additional conditions such as Hereditary Tyrosinemia Type 1 (HT1), a rare inherited condition that can cause serious health problems if not identified and treated early.

Earlier diagnosis gives babies the best possible chance of receiving treatment before symptoms develop or become more severe. This can improve long-term health outcomes and reduce the risk of serious illness, severe disability and, in some cases, death.

Newborn screening also provides reassurance for families during the first days of a baby’s life. While most babies will not be affected by the conditions screened for, those who are can benefit from earlier access to treatment, support and specialist services.

Abigail Holmes, Director of Midwifery & Neonatal Services said:

“Supporting families through the first days of their baby’s life is an important part of our role as midwives. Newborn blood spot screening is a routine part of the care we provide and helps give families reassurance during those early days with their new baby. While most babies screened will not have any of the conditions being tested for, for those who do, screening can help ensure they receive the right care and support as early as possible. This new laboratory facility will help strengthen newborn screening services and support families across Wales for years to come.”

Professor Stuart Moat, Consultant Clinical Biochemist and Director of the Wales Newborn Screening Laboratory said:

“This investment marks a significant step forward for newborn screening in Wales. It will both strengthen and stabilise our current laboratory service and create the infrastructure needed to expand screening for additional rare but serious treatable conditions, ensuring that babies can benefit from early diagnosis and timely intervention.”